banner
Home>Products & Services> Sitagliptin Phosphate Monohydrate

Sitagliptin Phosphate Monohydrate

Sitagliptin Phosphate Monohydrate

Synonym

7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)Butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazinephosphatemonohydrate

CAS #

654671-77-9

Molecular Formula

C16H20F6N5O6P

Molecular Weight

523.32

Structure

CAS 654671-77-9

US-DMF No. 29226
IRAN- 876543 P/251

Sitagliptin (INN; i/sɪtəˈɡlɪptɪn/, previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of this medicine is its fewer side effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. While safety is its advantage, efficacy is often challenged as it is often recommended to be combined with other agents such as metformin.